Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
28/07/2023 16:25
July 28 (Reuters) - Chinook Therapeutics Inc KDNY.O :
* CHINOOK THERAPEUTICS ANNOUNCES FIRST PATIENT ENROLLED IN
PIVOTAL
PHASE 3 BEYOND STUDY OF ZIGAKIBART (BION-1301) FOR PATIENTS WITH
IGA NEPHROPATHY
Source text for Eikon: ID:nGNXbcHhGR
Further company coverage: KDNY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chinook Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Chinook Therapeutics
Chinook Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Chinook Therapeutics Inc expected to post a loss of 81 cents a share - Earnings Preview
Brief: Chinook Therapeutics Announces First Patient Enrolled In Phase 3 Of Zigakibart
Brief: Muddy Waters- Remains Short On Chinook Therapeutics Inc